EyePoint Inc. (EYPT)
NASDAQ: EYPTIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 3.37 +1.48%
EYPT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $278.35M
- EPS (TTM)
- -$3.75
- Dividend yield
- None
- 52-week range
- 3.05 – 19.11
- Day range
- 3.09 – 3.42
- Volume / Avg
- 3.02M / 3.93M
- Beta
- —
- Shares outstanding
- 83.84M
- Next earnings
- Nov 4, 2026
52-week range
EYPT stock today
Shares of EyePoint (EYPT) finished higher on Oct 7 at $3.32, a gain of 4.73% or $0.15 per share, versus the S&P 500's 0.22% decline. At this level, EYPT sits near the bottom of its 52-week range of $3.05 to $19.11: 82.6% below the high, set on Dec 8, 2025 and 8.9% above the low. EYPT is down 81.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 74.9%.
EyePoint has posted a net loss over the last twelve months (EPS of -$3.75), so its P/E ratio is not meaningful. EyePoint's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About EyePoint
Company profileEyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Jay S. Duker M.D.
- Headquarters
- Watertown, MA
- Employees
- 214
- Website
- eyepoint.bio
Analyst forecast
ForecastConsensus (13 analysts)
none
Avg. price target
$25.91+680.42%
- Strong buy 1
- Buy 6
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.81
EYPT news
All EYPT newsEyePoint peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LABStandard BioTools Inc. | 0.6787 | -6.00% | $266.44M | vs EYPT |
| NAUTNautilus Biotechnology Inc. | 1.96 | +10.73% | $249.42M | vs EYPT |
| QTRXQuanterix Corporation | 3.33 | -3.34% | $157.25M | vs EYPT |
| SEERSeer Inc. Class A | 2.21 | +0.91% | $122.37M | vs EYPT |
| CIRCCircle8 Group Inc. | 0.46 | -7.26% | $52.63M | vs EYPT |
| RPIDRapid Micro Biosystems Inc. Class A | 0.8977 | -4.76% | $45.03M | vs EYPT |
| PRPOPrecipio Inc. | 23.52 | +0.30% | $42.11M | vs EYPT |
| HBIOHarvard Bioscience Inc. | 8.50 | -0.70% | $38.69M | vs EYPT |
Indexes, lists and sector
EyePoint stock FAQ
What is EyePoint's stock price today?
EYPT last traded at $3.32 as of Oct 7, 4:00 PM EDT, up 4.73% on the day. Prices are delayed at least 15 minutes.
Does EyePoint pay a dividend?
No. EyePoint does not currently pay a regular cash dividend.
When is EyePoint's next earnings date?
EyePoint is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.81.
Who is EyePoint's CEO?
Dr. Jay S. Duker M.D. is the chief executive officer of EyePoint Inc., which has about 214 employees.
Has EYPT ever split its stock?
Yes. The most recent EYPT stock split was a 1-for-10 split on Dec 9, 2020, one of 2 splits on record.
What is the EYPT 52-week high?
The 52-week high for EYPT is $19.11 and the 52-week low is $3.05. The stock is currently 82.6% below its high.